Ultima Genomics Adds Former Thermo Fisher Exec Mark Stevenson to Board of Directors

Mark Stevenson, with more than 30 years of experience in the life sciences sector, formerly Executive Vice President and Chief Operating Officer of Thermo Fisher Scientific joins Ultima Genomics’ Board of Directors

FREMONT, Calif.--(BUSINESS WIRE)-- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that Mark Stevenson will join its Board of Directors. Mark brings more than 30 years of experience and leadership in the Life Sciences sector, most recently serving as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, where he was responsible for the portfolio of life science, analytical and diagnostic businesses as well as the innovation and digital strategy.

“Mark brings a wealth of valuable experience having led the innovation and commercial launch of a range of next-generation sequencing technologies now broadly used across both the life sciences research and clinical markets,” said Gilad Almogy, CEO and founder of Ultima Genomics. “Mark is an accomplished leader in life sciences and a tenured executive, advisor and board member for large and global organizations. His background and leadership experience will be a tremendous asset as we build upon the successful launch of our first system using our new sequencing architecture.”

“Ultima has demonstrated a commitment to challenging the conventional approach, shown through its progress in maturing such a differentiated technology,” said Mark Stevenson. “We are still in the early days of genomics’ impact on healthcare, and technological advancements like Ultima’s sequencing technology will enable more research and better clinical tests to advance the life sciences field. I believe this technology has the potential to open entirely new opportunities to deploy genomics at scale.”

Mark continues to serve on the Scientific Advisory Board of Thermo Fisher Scientific. He is also on the boards of Ingersoll Rand Inc. (NYSE: IR), and Harbinger Health and is a senior advisor at General Atlantic.

About Ultima Genomics

Ultima Genomics is unleashing the power of genomics at scale. The Company’s mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology’s complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima’s revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240502202274/en/